Clinical trial NCT04976803: Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
Official title: A Tissue Collection Study to Explore the Correlation Between ATM Genetic Alterations by Next-Generation Sequencing and ATM Loss-of-Protein Via IHC (ATR-ID Study)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Solid Tumor, Unspecified, Adult
Keywords: ATM
DDR
ATR
protein expression
LoF
Lead sponsor: Artios Pharma Ltd
Sponsor class: INDUSTRY
First posted: 2021-07-26
Enrollment: 229
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with identified ATM alterations will be potentially enrolled into this study in 1 of 3 patient populations

* Group A: Deceased patients with archival tumor tissue
* Group B: Living patients with archival tumor tissue
* Group C: Living patients without archival tumor tissue

Brief summary: This study examines the correlation between ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Detailed description: The purpose of this study is to address whether ATM genomic aberrations could be used to enrich for patients with ATM LoP. Screening of unselected patient populations for ATM protein loss is likely to a lead to high failure rate by IHC testing, as the prevalence of this is expected to be low. This study could allow for identification of the types of ATM aberrations that lead to ATM LoP, and thus significantly decrease IHC failure rate by pre-selecting patients harboring such aberrations. In this study the investigator will be collecting archival tumor tissue or fresh tissue which will be assessed for ATM LoP and compared to NGS data. Additionally, patients whose tumors exhibit ATM LoP within this study could potentially enroll onto the treatment study REFMAL 721/ART0380C001.

Eligibility criteria: Inclusion Criteria:

* Patients must meet the following criteria in order to be included in the research study:

All patients (Groups A, B, and C) must meet the following criteria:

1. Previous genetic testing of ATM genomic aberrations.
2. ≥18 years of age.

   All living patients (Groups B and C) must also meet the additional criteria:
3. Signed written informed consent to access archival tissue, if available.

   All Group C patients must also meet the additional criteria:
4. Provided signed written informed consent to collect a fresh core biopsy.
5. Have a non-irradiated, biopsiable tumor site to allow sampling for analysis via IHC for loss of ATM protein.
6. Potentially eligible for REFMAL 721/ART0380C001:

   * Have not received a previous treatment targeting the ATR/CHK1 pathway.
   * If patients have a germline BRCA mutation or a cancer with a somatic BRCA mutation or which is HRD positive and for which there is an approved PARP inhibitor, patients should have received such treatment.
   * Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator
   * Advanced or metastatic cancer which is refractory to standard therapies, or for which no standard therapies exist, or for which the investigator feels no other active therapy is required for the duration of the study.
   * Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale

Exclusion Criteria:

There are no exclusion criteria for patients in Group A and Group B.

Group C patients who meet any of the following criteria will be excluded from study entry:

1. Have a significant bleeding disorder or vasculitis or had a Grade 3 bleeding episode within 12 weeks prior to enrollment.
2. Presumed ineligible for enrollment to REFMAL 721/ART0380C001:

   * Psychological, familial, sociological, or geographical conditions that that would compromise the patient's ability to adhere to future procedures likely in a Phase I protocol (such as REFMAL 721/ ART0380C001).
   * Women who are pregnant, breast feeding, or who plan to become pregnant within the next 6 months.
   * Men who plan to father a child within the next 6 months.
   * Have a serious concomitant systemic disorder that would compromise the patient's ability to adhere to a future protocol (REFMAL 721/ ART0380C001) including:

     1. One or more opportunistic HIV/AIDs-related infections within the past 12 months.
     2. Documented active or chronic infection with hepatitis B virus (positive hepatitis B surface antigen \[+HBsAg\]), or hepatitis C virus.
     3. Known history of clinical diagnosis of tuberculosis.
     4. Have had a malignancy prior to the current malignancy. Patients with carcinoma in situ of any origin and patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma), as judged by the medical monitor, are eligible for this study.
   * Have evidence of interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic).
   * Have moderate or severe cardiovascular disease, such as the following:

     1. Have the presence of cardiac disease.
     2. Have valvulopathy that is severe, moderate, or deemed clinically significant.
     3. Have documented major electrocardiogram (ECG) abnormalities which are clinically significant.
   * Have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids (patients receiving anticonvulsants are eligible).

Primary outcomes:
measure: Number of patients with loss of ATM protein
timeFrame: 12 months
Secondary outcomes:
measure: Number of potential patients with loss of ATM protein eligible for study REFMAL 721/ART0380C001
timeFrame: 12 months
measure: Number of ATM genomic aberrations that lead to ATM LoP
timeFrame: 12 months
measure: Rate of loss of function (LoF) of the ATM gene in patients with genomic aberrations in the ATM gene
timeFrame: 12 months
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: Oklahoma University
state: Oklahoma
city: Nashville
country: United States
facility: Tennessee Oncology
state: Tennessee
city: London
country: United Kingdom
facility: Sarah Cannon Research UK
Study officials:
affiliation: Sarah Cannon
name: Melissa Johnson, MD
role: STUDY_CHAIR
References: